A Phase 2 Trial for Patients With Metastatic Solid Cancer

Phase 2 Unknown 32 enrolled Rampart Health, L.L.C.

NaSingle-groupOpen-labelTreatment

This study seeks to estimate the potential efficacy of the study treatment, as well as the occurrence of adverse events.

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	50 mg	Other
Subject	Cyclophosphamide	Other / unclassified	250 mg/m2	Other
Subject	GM-CSF	Protein / enzyme biologic	250 ug	Subcutaneous
Subject	Ipilimumab	Monoclonal antibody	2 ml	Other
Subject	Pembrolizumab	Monoclonal antibody	2 ml	Other